Articles by Lauren Dembeck, PhD
A four-strain probiotic is safe and shows symptom relief trend in patients with IBD/IBS overlap, study shows.
Steroids and comorbidities—not IBD itself—drive pneumonia risk in IBD, study finds.
FDA authorizes CLAIRITY BREAST, the first AI tool to predict 5-year breast cancer risk from screening mammograms.
NF1-mutant melanoma may respond to EGFR inhibitors, offering hope for patients resistant to immunotherapy.
Digital inhaler data may predict COPD exacerbations up to 14 days early, offering a potential remote monitoring tool.
Lifestyle and metformin interventions cut diabetes risk for 21 years in adults with prediabetes, DPP study shows.
Black youth with dysglycemia show reduced insulin clearance, possibly contributing to β-cell dysfunction and ...
Real-world weight loss with semaglutide or tirzepatide is lower due to early discontinuation and low maintenance dosing.
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Elinzanetant reduces vasomotor symptoms from endocrine therapy in HR+ breast cancer, with rapid onset and good tolerability.
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
About 1 in 10 patients with high RS early HR+/HER2- BC decline chemo, which is tied to worse overall survival, per ASCO data.
Oral paclitaxel (DHP107) shows non-inferior efficacy and manageable safety vs IV in HER2-negative metastatic breast cancer.
Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.
Sacituzumab tirumotecan showed a 71% ORR and manageable safety in first-line advanced TNBC, regardless of PD-L1 status.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.